#6 - Merck & Company (NYSE:MRK)
Merck & Company (NYSE:MRK) is a best-in-breed pharmaceutical stock. However, the stock has been under-the-radar of some investors because it’s not part of the Covid-19 vaccine race. This was evident in the fact that MRK stock dropped 10% in 2020. Some of that is attributable to the company spinning off several of its business units, and the associated $6.5 billion in revenue, to a different company.
However, the company still has a strong performer in its oncology drug, Keytruda, which delivered a record $14 billion in revenue in 2020 and is on pace to do even better in 2021. Investors will certainly note that Keytruda has patent protection in the United States for another six years. And in the European Union and Japan the protections go even further.
Analysts have a consensus price target that gives MRK stock a 20% upside. The stock has paid out a dividend for the last 11 years.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Read More - Current Price
- $129.48
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $133.00 (2.7% Upside)
